ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Jupiter Neurosciences Inc

Jupiter Neurosciences Inc (JUNS)

3.58
-1.84
(-33.95%)
Closed January 22 3:00PM
3.65
0.07
(1.96%)
After Hours: 6:01PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
3.65
Bid
3.64
Ask
3.65
Volume
6,872,287
3.00 Day's Range 5.60
3.89 52 Week Range 19.51
Market Cap
Previous Close
5.42
Open
5.60
Last Trade
45
@
3.65
Last Trade Time
Financial Volume
US$ 26,159,457
VWAP
3.8065
Average Volume (3m)
499,875
Shares Outstanding
33,103,860
Dividend Yield
-
PE Ratio
-24.98
Earnings Per Share (EPS)
-0.14
Revenue
-
Net Profit
-4.78M

About Jupiter Neurosciences Inc

Jupiter Neurosciences is a clinical stage research and development pharmaceutical company. The Company has developed a unique resveratrol platform product targeting treatment of neuro-inflammation. The product, called JOTROL¿ , has many potential indications of use for rare diseases, which of we pri... Jupiter Neurosciences is a clinical stage research and development pharmaceutical company. The Company has developed a unique resveratrol platform product targeting treatment of neuro-inflammation. The product, called JOTROL¿ , has many potential indications of use for rare diseases, which of we primarily are targeting Mucopolysaccharidoses Type 1, Friedreichs Ataxia, and MELAS as well as ALS which is in an early development stage. In the larger disease areas, we are primarily targeting Mild Cognitive Impairment/early Alzheimers disease with TBI/concussions and Covid-19 in early development stages. Based on available scientific literature, we believe that JOTROL¿ is the first and only resveratrol product in the world that delivers a therapeutically effective dose of resveratrol in the blood stream without causing gastrointestinal side effects. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Jupiter Neurosciences Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker JUNS. The last closing price for Jupiter Neurosciences was US$5.42. Over the last year, Jupiter Neurosciences shares have traded in a share price range of US$ 3.89 to US$ 19.51.

Jupiter Neurosciences currently has 33,103,860 shares outstanding. The market capitalization of Jupiter Neurosciences is US$179.42 million. Jupiter Neurosciences has a price to earnings ratio (PE ratio) of -24.98.

JUNS Latest News

Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ Trials

Jupiter, Florida, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a...

Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering

Jupiter, Florida, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (Nasdaq: JUNS) (the “Company” or “Jupiter Neurosciences”), a clinical stage pharmaceutical company advancing a...

Jupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq

Jupiter, Florida, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (Nasdaq: JUNS) (the “Company” or “Jupiter Neurosciences”), a clinical stage pharmaceutical company advancing a...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-2.33-38.96321070235.986.484.114078364.54856615CS
4-8.23-69.276094276111.8812.54.115102897.77426258CS
12-0.35-8.75419.513.894998758.93047617CS
26-0.35-8.75419.513.894998758.93047617CS
52-0.35-8.75419.513.894998758.93047617CS
156-0.35-8.75419.513.894998758.93047617CS
260-0.35-8.75419.513.894998758.93047617CS

JUNS - Frequently Asked Questions (FAQ)

What is the current Jupiter Neurosciences share price?
The current share price of Jupiter Neurosciences is US$ 3.65
How many Jupiter Neurosciences shares are in issue?
Jupiter Neurosciences has 33,103,860 shares in issue
What is the market cap of Jupiter Neurosciences?
The market capitalisation of Jupiter Neurosciences is USD 179.42M
What is the 1 year trading range for Jupiter Neurosciences share price?
Jupiter Neurosciences has traded in the range of US$ 3.89 to US$ 19.51 during the past year
What is the PE ratio of Jupiter Neurosciences?
The price to earnings ratio of Jupiter Neurosciences is -24.98
What is the reporting currency for Jupiter Neurosciences?
Jupiter Neurosciences reports financial results in USD
What is the latest annual profit for Jupiter Neurosciences?
The latest annual profit of Jupiter Neurosciences is USD -4.78M
What is the registered address of Jupiter Neurosciences?
The registered address for Jupiter Neurosciences is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Jupiter Neurosciences website address?
The website address for Jupiter Neurosciences is www.jupiterneurosciences.com
Which industry sector does Jupiter Neurosciences operate in?
Jupiter Neurosciences operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BLBXBlackBoxStocks Inc
US$ 5.53
(227.22%)
229.07M
ASSTAsset Entities Inc
US$ 1.36
(51.11%)
121.67M
STAIScanTech AI Systems Inc
US$ 2.12
(44.22%)
51.68M
JYDJayud Global Logistics Ltd
US$ 3.53
(42.91%)
1.27M
NTRBNutriband Inc
US$ 7.39
(41.84%)
3.88M
STFSStar Fashion Culture Holdings Ltd
US$ 2.62
(-80.61%)
30.25M
HEPAHepion Pharmaceuticals Inc
US$ 0.135
(-58.05%)
39.89M
STBXStarBox Group Holdings Ltd
US$ 0.6201
(-36.50%)
1.63M
WHLRLWheeler Real Estate Investment Trust Inc
US$ 93.51
(-35.73%)
1
JUNSJupiter Neurosciences Inc
US$ 3.61
(-33.39%)
6.87M
IPAImmunoPrecise Antibodies Ltd
US$ 0.6446
(30.75%)
296.43M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.3191
(33.57%)
229.11M
BLBXBlackBoxStocks Inc
US$ 5.53
(227.22%)
229.08M
NVDANVIDIA Corporation
US$ 147.07
(4.43%)
216.62M
RGTIRigetti Computing Inc
US$ 13.89
(-0.64%)
154.54M

JUNS Discussion

View Posts
tw0122 tw0122 1 month ago
Back down to $11 halt 38% 
👍️0
Invest-in-America Invest-in-America 1 month ago
JUNS: WHERE do you see that 120%??? Is that your price TARGET??? (Etrade, etc.,.shows only 38%.)
👍️0
tw0122 tw0122 1 month ago
$17 +120%
👍️0
Invest-in-America Invest-in-America 1 month ago
JUNS: O.K., sounds fine to me, Homeboy!!
👍️0
tw0122 tw0122 1 month ago
From Saturn off to Jupiter $11.79 + 50%
👍️0
Invest-in-America Invest-in-America 2 years ago
JUNS (IPO):
👍️0
makinezmoney makinezmoney 2 years ago
$JUNS: IPO is launching next week

We are waiting on it.



Jupiter Neurosciences, Inc. has developed the first and only resveratrol product that safely reaches therapeutic levels without GI-side effects creating treatment possibilities in many indications.

https://jupiterneurosciences.com/








GO $JUNS
👍️0
Invest-in-America Invest-in-America 2 years ago
JUNS: Evidently, now ready-to-go on E-Turd, Fidelity, etc.
👍️0
spindog spindog 3 years ago
Ticker hasn’t shown up on E*TRADE yet
👍️0
crudeoil24 crudeoil24 3 years ago
IPO scheduled for February 3, 2022.
👍️0
crudeoil24 crudeoil24 3 years ago
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer’s disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.
👍️0

Your Recent History

Delayed Upgrade Clock